How We Work: HealthRX Clinical Process, Medical Standards, and Patient Safety

Step 1: You Complete a Structured Clinical Intake

Every HealthRX patient begins with a detailed health questionnaire, not a generic sign-up form. The intake captures current diagnoses, medication history, surgical history, family cardiovascular risk, and self-reported symptoms. This information feeds directly into a physician's chart review, not an algorithm.

Why the Intake Matters Clinically

Skipping a thorough intake is how telehealth platforms create harm. The FDA's 2023 guidance on prescribing GLP-1 receptor agonists specifically flags the need to screen for personal or family history of medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia syndrome type 2 (MEN 2) before initiating semaglutide or tirzepatide. Semaglutide (Wegovy) FDA label [1]. Our intake includes both contraindication screens verbatim.

For testosterone replacement therapy, the American Urological Association and the Endocrine Society recommend baseline measurement of total testosterone, hematocrit, PSA, and luteinizing hormone before any prescription is written [2]. Patients who skip those labs at other platforms may receive testosterone without knowing their hematocrit is already elevated, raising stroke risk.

What Happens to Your Intake Data

A licensed clinician, not a chatbot, reviews your chart. Intake responses are flagged by severity. Any response indicating active chest pain, uncontrolled type 1 diabetes with frequent DKA, or a contraindicated co-medication triggers an immediate clinical hold and a message directing you to emergency or in-person care.

Step 2: Lab Work Is Reviewed Before Any Prescription

Baseline laboratory testing is non-negotiable for hormone and metabolic therapies at HealthRX. You may use labs drawn within the last 90 days from any accredited U.S. Laboratory, or we coordinate a draw through our partner network.

Labs Required by Therapy Type

GLP-1 therapy (semaglutide, tirzepatide, liraglutide): Fasting glucose, HbA1c, lipid panel, comprehensive metabolic panel (CMP), and thyroid-stimulating hormone (TSH). The American Diabetes Association's 2024 Standards of Care specify HbA1c as the primary diagnostic and monitoring metric for type 2 diabetes management, with a target of <7.0% for most non-pregnant adults [3].

Testosterone replacement therapy (TRT): Total testosterone (morning draw), free testosterone, sex hormone-binding globulin (SHBG), LH, FSH, PSA, hematocrit, and complete blood count. The Endocrine Society clinical practice guideline on male hypogonadism defines biochemical hypogonadism as a consistently low total testosterone below 300 ng/dL on two separate morning draws [2].

HRT (estrogen, progesterone, DHEA): FSH, estradiol, total testosterone, SHBG, TSH, CMP, and lipid panel. The Menopause Society (formerly NAMS) 2023 position statement notes that hormone therapy remains the most effective treatment for vasomotor symptoms and that individualized risk assessment, including cardiovascular and breast cancer history, must precede prescribing [4].

Peptide protocols (BPC-157, CJC-1295/Ipamorelin, Sermorelin): CMP, CBC, IGF-1, fasting insulin, and fasting glucose at minimum.

What Happens If Labs Are Out of Range

Any result that crosses a predefined safety threshold generates an automatic clinical hold. For example, a hematocrit above 50% in a patient requesting testosterone halts the prescription until a clinician reviews and either clears the finding or refers the patient to their primary care physician. This mirrors the 2018 Endocrine Society guideline recommendation to withhold TRT when hematocrit exceeds 54% [2].

Step 3: A Board-Certified Physician Reviews Your Full Chart

No HealthRX prescription is approved without physician review. Our clinicians hold active state licensure in every state where we operate. They are not nurse practitioners acting without physician oversight on hormone or metabolic therapy, though NPs and PAs on our team do collaborate under defined supervision protocols that meet or exceed each state's telemedicine practice act.

How the Physician Review Works

The reviewing clinician receives your intake questionnaire, your full lab panel with reference ranges, your medication list, and any prior records you have uploaded. The review is asynchronous by default, meaning the physician works through your chart on their own time within a defined window, typically 24 to 48 hours after lab receipt.

If a clinician needs clarification, they send a secure message through your patient portal. Most clarifications are resolved within one business day. Patients who prefer a synchronous video visit may book one at any stage; it is not required for straightforward cases with clean labs.

Prescribing Decisions Are Evidence-Anchored

Our physicians prescribe within FDA-approved indications as the first option. When off-label use is appropriate, for example, using semaglutide 1.0 mg (Ozempic) for weight management in a patient who cannot access Wegovy due to supply constraints, the prescribing physician documents the clinical rationale, references supporting literature, and notes the patient's informed consent. The FDA has explicitly stated that off-label prescribing is legal and common when supported by sound medical judgment [5].

The HealthRX Off-Label Prescribing Decision Framework requires three criteria to be met simultaneously: (1) at least one peer-reviewed trial supports the off-label indication in a population comparable to the patient, (2) the risk-benefit ratio is documented in the chart note, and (3) the patient receives written informed consent explaining that the use is not the FDA-approved indication. This framework applies to every peptide protocol and every off-label hormone dose we prescribe.

Step 4: Medications Are Dispensed Through Licensed Pharmacies

HealthRX does not operate its own compounding facility. Prescriptions are routed to state-licensed, FDA-registered pharmacies. For branded GLP-1 medications like Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide 2.5 to 15 mg), prescriptions go to licensed retail or specialty pharmacies. Compounded semaglutide or tirzepatide, where clinically appropriate and legally available, is dispensed only through 503B outsourcing facilities registered with the FDA [6].

Why 503A vs. 503B Matters

A 503A pharmacy compounds on a per-patient, per-prescription basis and is not required to meet the same sterility and testing standards as a 503B outsourcing facility. The FDA's guidance on compounded drug products distinguishes the two clearly [6]. HealthRX routes injectable compounds, including peptides and compounded hormones, exclusively through 503B facilities when available in that compound category.

Shipping and Cold Chain

Peptides and compounded hormones that require refrigeration are shipped with validated cold-chain packaging. Patients receive tracking information and temperature-excursion guidance. Any shipment that a patient reports arriving warm or damaged is replaced without charge after a brief clinical review to confirm the compound's integrity was likely compromised.

Step 5: Ongoing Monitoring Keeps You Safe After Prescribing

Starting a therapy is not the end of clinical responsibility. It is the beginning of a monitoring cycle.

Standard Follow-Up Schedule

• 30 days: Symptom check-in via secure message or portal questionnaire. Side-effect screening for GLP-1 patients includes nausea severity, GI tolerance, and injection-site reactions.
• 90 days: Repeat labs for most therapies. For GLP-1 patients, this includes HbA1c and fasting glucose. For TRT patients, this includes hematocrit, PSA, and total testosterone trough. The Endocrine Society recommends monitoring hematocrit at 3 to 6 months after TRT initiation and then annually [2].
• 180 days: Full lab panel plus physician chart review. Dose adjustments, therapy continuation, or de-escalation decisions are made at this visit.

Dose Titration Is Supervised

GLP-1 dose escalation follows the FDA-approved titration schedules. For semaglutide (Wegovy), the schedule is 0.25 mg weekly for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, then maintenance at 2.4 mg weekly [1]. Patients who cannot tolerate dose escalation due to GI side effects may remain at a lower dose for an extended period; the clinician documents this decision. Arbitrary acceleration of the titration schedule is not permitted on our platform.

In the STEP-1 trial (N=1,961), semaglutide 2.4 mg weekly produced a mean body weight reduction of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001) [7]. That result was achieved at the full maintenance dose following the standard titration. Rushing titration does not replicate the trial's safety profile.

When We Refer Out

Some findings require in-person evaluation that telehealth cannot safely provide. HealthRX clinicians refer patients to in-person care when:

• Hematocrit exceeds 54% on TRT
• PSA rises more than 1.4 ng/mL above baseline within 12 months on TRT
• HbA1c is above 10% at intake in a patient who has never been treated for diabetes
• Any symptom pattern suggests acute pancreatitis, a rare but documented risk with GLP-1 therapy noted in FDA prescribing information [1]

The Endocrine Society's position is explicit: "Patients with severe or rapidly worsening symptoms should be evaluated in person" [2]. We follow that direction without exception.

The Evidence Base Behind Our Protocols

HealthRX clinical protocols are built on primary literature, not marketing material. Below are the trial-level data points that anchor our most prescribed therapies.

GLP-1 Receptor Agonists

Semaglutide 2.4 mg weekly (Wegovy) was approved by the FDA in June 2021 for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity [1]. The STEP-1 trial supporting that approval enrolled 1,961 adults without diabetes and demonstrated 14.9% mean weight loss at 68 weeks [7]. The SELECT trial (N=17,604) subsequently showed that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% versus placebo in overweight or obese adults with established cardiovascular disease but without diabetes (HR 0.80, 95% CI 0.72 to 0.90, P<0.001) [8].

Tirzepatide (Zepbound), a dual GIP/GLP-1 receptor agonist, received FDA approval for weight management in November 2023. The SURMOUNT-1 trial (N=2,539) showed 20.9% mean weight loss at 72 weeks with the 15 mg dose versus 3.1% with placebo (P<0.001) [9].

Testosterone Replacement Therapy

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement in men with hypogonadism and high cardiovascular risk did not significantly increase the rate of major adverse cardiovascular events compared with placebo (HR 0.96, 95% CI 0.78 to 1.17) [10]. This trial resolved a decade of uncertainty about TRT cardiac safety and informed updated prescribing guidance.

Hormone Replacement Therapy

The Women's Health Initiative (WHI) initial 2002 report generated significant concern about combined estrogen-progestin HRT. Subsequent re-analysis by timing of initiation, the "timing hypothesis," showed that women who started HRT within 10 years of menopause or before age 60 had a lower all-cause mortality risk compared with placebo in a 2013 meta-analysis published in BMJ (RR 0.70, 95% CI 0.52 to 0.95) [11]. The Menopause Society's 2023 position statement incorporates this evidence in supporting individualized HRT prescribing [4].

What We Do Not Prescribe or Offer

Transparency about scope matters. HealthRX does not prescribe:

• Controlled substances for weight loss (e.g., phentermine-topiramate is prescribed only through our affiliated in-person network, not via asynchronous telehealth)
• Anabolic steroids for performance enhancement or bodybuilding
• Unapproved peptides not available through a licensed 503B facility
• Any medication to a patient who has not completed the required baseline labs

The FDA's regulatory framework for drug approval and compounding is the floor, not a ceiling, for our safety standards [5].

How Our Medical Team Is Credentialed

Every HealthRX prescribing clinician meets the following criteria before seeing patients:

1. Active, unrestricted medical license in the state where the patient resides
2. Board certification in a relevant specialty (internal medicine, family medicine, endocrinology, urology, or obstetrics and gynecology)
3. Completion of HealthRX's internal prescribing protocol review, covering our GLP-1, TRT, HRT, and peptide-specific guidelines
4. Annual continuing medical education in telehealth prescribing standards

Clinicians undergo periodic chart audits. Cases where a prescription was issued without complete labs, without a documented contraindication screen, or without a legible clinical rationale are flagged for remediation.

Patient Rights and Data Privacy

HealthRX operates under HIPAA. Your health information is stored in a HIPAA-compliant electronic health record and is never sold to third parties. The U.S. Department of Health and Human Services Office for Civil Rights enforces HIPAA's privacy and security rules, and HealthRX's data practices are audited annually for compliance [12].

You have the right to:

• Request a copy of your complete medical record at any time
• Request a transfer of your prescription to any licensed pharmacy
• Decline any recommended therapy without losing access to the platform
• Request that your data be deleted, subject to legal medical record retention requirements (typically 7 years in most states)

Frequently Asked Questions